AstraZeneca (France)

Tumor and ctDNA concordance of actionable alterations in metastatic breast cancer

As biomarker-driven therapies are available for hormone receptor-positive (HR+) metastatic breast cancer (MBC), identification of actionable alterations is critical for determining the optimal therapy. Both tissue and plasma ctDNA next-generation sequencing (NGS) assays can revea...

Treatment patterns and outcomes in US patients with unresectable HCC treated with embolization

Aims To describe treatment patterns and outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with embolization.Materials & methods This retrospective observational study used Optum’s de-identified Market Clarity Data. US adults with HCC treated with embo...

Characteristics, treatment patterns, and outcomes of patients with transthyretin amyloidosis: a large-scale, observational, retrospective study in China (OverTTuRe China)

Abstract Background Evidence remains limited on disease journey for transthyretin (ATTR) amyloidosis in China. This study aims to analyse China data from OverTTuRe, an observational, retrospective, multi-country cohort study. Methods Data were extracted from medical records (2013...

Incidence of New Malignancies in Severe Asthma: Comparison of Real-World Patients Treated with Benralizumab, Other Biologics, or Non-biologics

Clinical trials report no increased malignancy risk with benralizumab in severe asthma; however, trial populations are highly selective. To better define real-world safety, malignancy risk was compared among patients treated with benralizumab, other (non-benralizumab) biologics,...